MedTrace Logo

Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment

NCT01205477 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2010-09-20

No results posted yet for this study

Summary

To investigate the safety and efficacy of methylprednisolone infiltration in anserine bursitis treatment

Conditions

  • Bursitis

Interventions

DRUG

EXPERIMENTAL

Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days

DRUG

PLACEBO

Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days

Sponsors & Collaborators

  • Universidad Autonoma de Nuevo Leon

    lead OTHER

Principal Investigators

  • Mario Alberto Garza Elizondo, MD · Universidad Autónoma de Nuevo León

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01205477 on ClinicalTrials.gov